327 related articles for article (PubMed ID: 27256004)
21. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
[TBL] [Abstract][Full Text] [Related]
22. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
23. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
24. [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1543-6. PubMed ID: 25146741
[TBL] [Abstract][Full Text] [Related]
25. [Increased serum levels of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients infected with Brucella].
Pang P; Zhu Y; Jia B; Yang Y; Hu J; Zhang Y; Zhang F; Ding J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Dec; 32(12):1675-1678. PubMed ID: 27916101
[TBL] [Abstract][Full Text] [Related]
26. Soluble PD‑L1 reflects cachexia status in patients with gastric cancer and is an independent prognostic marker for relapse‑free survival after radical surgery.
Matsumoto Y; Sasaki T; Kano M; Shiraishi T; Suito H; Murakami K; Toyozumi T; Otsuka R; Kinoshita K; Iida S; Morishita H; Nishioka Y; Hayano K; Kurata Y; Hayashi H; Matsubara H
Mol Clin Oncol; 2023 May; 18(5):39. PubMed ID: 37035474
[TBL] [Abstract][Full Text] [Related]
27. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
28. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
Guo X; Wang J; Jin J; Chen H; Zhen Z; Jiang W; Lin T; Huang H; Xia Z; Sun X
Transl Oncol; 2018 Jun; 11(3):779-785. PubMed ID: 29698935
[TBL] [Abstract][Full Text] [Related]
29. Serum sPD-L1, Upregulated in Sepsis, May Reflect Disease Severity and Clinical Outcomes in Septic Patients.
Liu M; Zhang X; Chen H; Wang G; Zhang J; Dong P; Liu Y; An S; Wang L
Scand J Immunol; 2017 Jan; 85(1):66-72. PubMed ID: 27864994
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
31. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
32. [Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy].
Muneoka K; Shirai Y; Sasaki M; Honma S; Sakata J; Kanda J; Wakabayashi H; Wakai T; Miyazaki M
Gan To Kagaku Ryoho; 2018 Aug; 45(8):1159-1163. PubMed ID: 30158411
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis.
Yanaba K; Hayashi M; Yoshihara Y; Nakagawa H
J Dermatol; 2016 Aug; 43(8):954-7. PubMed ID: 26945563
[TBL] [Abstract][Full Text] [Related]
34. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS
Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279
[TBL] [Abstract][Full Text] [Related]
35. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.
Han B; Dong L; Zhou J; Yang Y; Guo J; Xuan Q; Gao K; Xu Z; Lei W; Wang J; Zhang Q
Cancer Immunol Immunother; 2021 Oct; 70(10):2893-2909. PubMed ID: 33688997
[TBL] [Abstract][Full Text] [Related]
36. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines.
Chen Y; Wang Q; Shi B; Xu P; Hu Z; Bai L; Zhang X
Cytokine; 2011 Nov; 56(2):231-8. PubMed ID: 21733718
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
Kim HJ; Park S; Kim KJ; Seong J
Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
[TBL] [Abstract][Full Text] [Related]
38. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
40. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]